According to @mcuban, Cost Plus Drugs can bring tablet manufacturing of generic OTC and prescription drugs to the United States within about a year if the FDA waives Abbreviated New Drug Application (ANDA) fees, which he quantified as $365,000 per drug and $365 million for 1,000 filings (source: @mcuban on X, Dec 6, 2025). @mcuban stated that ingredients and manufacturing costs are the same for OTC and Rx tablets, enabling sales on CostPlusDrugs.com and TrumpRx at the same or lower prices than overseas-made products if fees are waived (source: @mcuban on X, Dec 6, 2025). @mcuban framed the fee waiver as unlocking domestic competition and lower drug prices via transparency and local manufacturing, contingent on FDA action (source: @mcuban on X, Dec 6, 2025). Dr. Marty Makary stated the FDA will cut red tape to deliver more safe and affordable OTC drugs, indicating regulatory momentum on OTC expansions per his statement (source: @DrMakaryFDA on X, cited by @mcuban, Dec 6, 2025). No direct crypto market linkage or impact on digital assets was cited in these statements (source: @mcuban and @DrMakaryFDA on X, Dec 6, 2025).

According to Mark Cuban on Twitter, Cost Plus Drugs has announced partnerships with several transparent, pass-through pharmacy benefit managers (PBMs), encouraging decision-makers to consult these PBMs before finalizing any corporate pharmacy benefits (Source: @mcuban, May 6, 2025). For investors and trading professionals in the healthcare and pharmaceutical sectors, this move signals a shift towards greater price transparency and potentially lower drug costs, which could impact the stock performance of traditional PBMs and benefit transparency-focused companies.